Aravive (NASDAQ:ARAV) had its price target lifted by Wedbush from $12.00 to $28.00 in a report released on Wednesday morning, The Fly reports. Wedbush currently has an outperform rating on the stock.
Several other analysts also recently commented on the stock. ValuEngine raised shares of Aravive from a buy rating to a strong-buy rating in a report on Friday, November 1st. HC Wainwright reaffirmed a buy rating and set a $31.00 target price (up previously from $18.00) on shares of Aravive in a report on Wednesday. Zacks Investment Research downgraded shares of Aravive from a buy rating to a hold rating in a report on Thursday, October 24th. Finally, Piper Jaffray Companies lifted their target price on shares of Aravive from $15.00 to $36.00 and gave the stock an overweight rating in a report on Tuesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $25.69.
Shares of ARAV traded up $0.36 during midday trading on Wednesday, reaching $10.00. The stock had a trading volume of 1,726,412 shares, compared to its average volume of 96,247. The firm has a market cap of $76.36 million, a PE ratio of -0.94 and a beta of 2.17. The company has a current ratio of 7.59, a quick ratio of 7.59 and a debt-to-equity ratio of 0.18. The firm has a 50 day simple moving average of $6.72 and a 200-day simple moving average of $6.31. Aravive has a one year low of $3.07 and a one year high of $15.62.
Aravive (NASDAQ:ARAV) last announced its earnings results on Thursday, November 7th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.04). As a group, research analysts forecast that Aravive will post -1.78 EPS for the current fiscal year.
In related news, CEO Jay Shepard sold 4,004 shares of Aravive stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. Insiders own 39.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in Aravive by 13.8% in the 2nd quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after purchasing an additional 18,017 shares during the period. Vanguard Group Inc. boosted its holdings in Aravive by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after purchasing an additional 7,200 shares during the period. BlackRock Inc. boosted its holdings in Aravive by 5.8% in the 2nd quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after purchasing an additional 9,544 shares during the period. Finally, Artal Group S.A. boosted its holdings in Aravive by 20.0% in the 2nd quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after purchasing an additional 51,197 shares during the period. 28.24% of the stock is owned by hedge funds and other institutional investors.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Read More: G-20
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.